share_log

United Therapeutics Analyst Ratings

ユナイテッド・セラピューティクスのアナリスト評価

Benzinga ·  2023/11/02 09:13
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/02/2023 37.45% Wedbush $307 → $308 Maintains Outperform
08/03/2023 41.91% Morgan Stanley $316 → $318 Maintains Overweight
08/03/2023 19.6% Ladenburg Thalmann $256 → $268 Maintains Buy
08/03/2023 37% Wedbush $305 → $307 Maintains Outperform
08/03/2023 33.88% HC Wainwright & Co. → $300 Reiterates Buy → Buy
05/04/2023 14.24% Ladenburg Thalmann $285 → $256 Maintains Buy
04/21/2023 24.96% Argus Research $300 → $280 Maintains Buy
04/10/2023 38.34% UBS $330 → $310 Maintains Buy
04/10/2023 41.02% Morgan Stanley $320 → $316 Maintains Overweight
02/23/2023 24.96% JP Morgan $265 → $280 Maintains Overweight
02/23/2023 42.81% Morgan Stanley $330 → $320 Maintains Overweight
02/23/2023 33.88% HC Wainwright & Co. → $300 Reiterates → Buy
01/11/2023 33.88% Argus Research $250 → $300 Maintains Buy
12/06/2022 47.27% Morgan Stanley $322 → $330 Maintains Overweight
12/06/2022 42.81% UBS → $320 Initiates Coverage On → Buy
12/05/2022 2.64% Goldman Sachs → $230 Initiates Coverage On → Sell
11/03/2022 18.26% JP Morgan $240 → $265 Maintains Overweight
11/03/2022 43.7% Morgan Stanley $288 → $322 Maintains Overweight
11/03/2022 67.35% Oppenheimer $325 → $375 Maintains Outperform
11/03/2022 33.88% HC Wainwright & Co. $255 → $300 Maintains Buy
10/11/2022 28.53% Morgan Stanley → $288 Initiates Coverage On → Overweight
05/24/2022 6.21% JP Morgan $225 → $238 Maintains Overweight
05/24/2022 9.34% Jefferies $223 → $245 Maintains Buy
05/24/2022 17.37% Wedbush $236 → $263 Maintains Outperform
05/24/2022 10.23% Credit Suisse $219 → $247 Maintains Outperform
05/24/2022 13.8% HC Wainwright & Co. $248 → $255 Maintains Buy
04/19/2022 -0.48% JP Morgan $230 → $223 Maintains Overweight
02/28/2022 5.32% Wedbush $276 → $236 Maintains Outperform
02/25/2022 -9.41% Ladenburg Thalmann $231 → $203 Maintains Buy
02/11/2022 BTIG Initiates Coverage On → Neutral
07/14/2021 -8.51% Argus Research → $205 Upgrades Hold → Buy
05/06/2021 10.67% HC Wainwright & Co. $195 → $248 Maintains Buy
04/08/2021 -5.39% JP Morgan $185 → $212 Maintains Overweight
02/22/2021 -12.53% Credit Suisse $169 → $196 Maintains Outperform
02/16/2021 22.72% Oppenheimer $200 → $275 Maintains Outperform
02/01/2021 -12.98% HC Wainwright & Co. $125 → $195 Upgrades Neutral → Buy
07/30/2020 -26.37% Oppenheimer $155 → $165 Maintains Outperform
07/30/2020 8.89% Wedbush $243 → $244 Maintains Outperform
06/25/2020 -35.29% Credit Suisse $129 → $145 Maintains Outperform
06/25/2020 -44.22% HC Wainwright & Co. $85 → $125 Maintains Neutral
03/10/2020 -45.11% Jefferies $115 → $123 Upgrades Hold → Buy
02/27/2020 -35.29% Cowen & Co. $119 → $145 Upgrades Market Perform → Outperform
02/13/2020 -46% Credit Suisse $113 → $121 Maintains Outperform
01/31/2020 -46.45% JP Morgan $116 → $120 Upgrades Neutral → Overweight
08/01/2019 -52.7% Ladenburg Thalmann $103 → $106 Upgrades Neutral → Buy
08/01/2019 -59.84% Jefferies → $90 Upgrades Underperform → Hold
07/01/2019 Credit Suisse Upgrades Neutral → Outperform
05/17/2019 -58.05% UBS $115 → $94 Upgrades Sell → Neutral
05/09/2019 Credit Suisse Upgrades Underperform → Neutral
05/02/2019 21.83% Wedbush $269 → $273 Maintains Outperform
03/01/2019 -57.6% Barclays $100 → $95 Maintains Underweight
11/19/2018 -53.14% Credit Suisse $103 → $105 Maintains Underperform
11/02/2018 -43.77% JP Morgan $118 → $126 Maintains Neutral

What is the target price for United Therapeutics (UTHR)?

The latest price target for United Therapeutics (NASDAQ: UTHR) was reported by Wedbush on November 2, 2023. The analyst firm set a price target for $308.00 expecting UTHR to rise to within 12 months (a possible 37.45% upside). 20 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for United Therapeutics (UTHR)?

The latest analyst rating for United Therapeutics (NASDAQ: UTHR) was provided by Wedbush, and United Therapeutics maintained their outperform rating.

When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.

Is the Analyst Rating United Therapeutics (UTHR) correct?

While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $307.00 to $308.00. The current price United Therapeutics (UTHR) is trading at is $224.08, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする